Loading organizations...
Biogazelle is a contract research organization based in Ghent, Belgium, that provides specialized genomic laboratory services focusing on nucleic acid quantification and clinical diagnostics. The enterprise supports pharmaceutical companies, biotechnology firms, and academic institutions with advanced digital PCR, quantitative PCR, and RNA sequencing assays tailored for complex immuno-oncology and cell and gene therapy applications. Operating through a fee-for-service business model that includes software licensing and contract research, the company scaled its operations to employ approximately 50 full-time personnel prior to its eventual buyout. The diagnostic laboratory received early financial backing from institutional investors including BNP Paribas Fortis, Qbic, and PMV before being acquired by global precision medicine provider CellCarta in December 2021. Biogazelle was originally founded in 2007 as a commercial spin-off from Ghent University by co-founders Jan Hellemans and Jo Vandesompele.
Biogazelle has raised $2.5M across 1 funding round.
Biogazelle has raised $2.5M in total across 1 funding round.
Biogazelle has raised $2.5M across 1 funding round. Most recently, it raised $2.5M Series B in October 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 10, 2014 | $2.5M Series B | — | Fondation Fournier Majoie, Qbic, SoFi | Announced |
Biogazelle has raised $2.5M in total across 1 funding round.
Biogazelle's investors include Fondation Fournier-Majoie, Qbic, SOFI.
